• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Regulation of lipid metabolism by obeticholic acid in hyperlipidemic hamsters.奥贝胆酸对高脂血症仓鼠脂质代谢的调节作用
J Lipid Res. 2017 Feb;58(2):350-363. doi: 10.1194/jlr.M070888. Epub 2016 Dec 9.
2
Activation of FXR by obeticholic acid induces hepatic gene expression of SR-BI through a novel mechanism of transcriptional synergy with the nuclear receptor LXR.奥贝胆酸通过激活法尼醇 X 受体(FXR),通过与核受体 LXR 的转录协同作用的新机制,诱导肝内清道夫受体 B1(SR-BI)的基因表达。
Int J Mol Med. 2019 May;43(5):1927-1938. doi: 10.3892/ijmm.2019.4136. Epub 2019 Mar 18.
3
Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the Diet-Induced NASH (DIN) hamster model.奥贝胆酸可升高饮食诱导非酒精性脂肪性肝炎(DIN)模型中 LDL-胆固醇并降低 HDL-胆固醇。
Eur J Pharmacol. 2018 Jan 5;818:449-456. doi: 10.1016/j.ejphar.2017.11.021. Epub 2017 Nov 16.
4
Farnesoid X Receptor Activation by Obeticholic Acid Elevates Liver Low-Density Lipoprotein Receptor Expression by mRNA Stabilization and Reduces Plasma Low-Density Lipoprotein Cholesterol in Mice.法尼醇 X 受体激动剂奥贝胆酸通过稳定 mRNA 水平升高肝脏低密度脂蛋白受体表达,并降低小鼠血浆中低密度脂蛋白胆固醇。
Arterioscler Thromb Vasc Biol. 2018 Oct;38(10):2448-2459. doi: 10.1161/ATVBAHA.118.311122.
5
FXR activation promotes intestinal cholesterol excretion and attenuates hyperlipidemia in SR-B1-deficient mice fed a high-fat and high-cholesterol diet.法尼酯X受体(FXR)激活可促进肠道胆固醇排泄,并减轻喂食高脂高胆固醇饮食的SR-B1基因缺陷小鼠的高脂血症。
Physiol Rep. 2020 Mar;8(5):e14387. doi: 10.14814/phy2.14387.
6
Regulation of scavenger receptor class B type I in hamster liver and Hep3B cells by endotoxin and cytokines.内毒素和细胞因子对仓鼠肝脏及Hep3B细胞中I型B类清道夫受体的调节作用
J Lipid Res. 2001 Oct;42(10):1636-44.
7
Activation of the farnesoid X receptor improves lipid metabolism in combined hyperlipidemic hamsters.法尼醇X受体的激活改善了混合型高脂血症仓鼠的脂质代谢。
Am J Physiol Endocrinol Metab. 2006 Apr;290(4):E716-22. doi: 10.1152/ajpendo.00355.2005. Epub 2005 Nov 15.
8
Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers.奥贝胆酸对健康志愿者脂蛋白代谢的影响。
Diabetes Obes Metab. 2016 Sep;18(9):936-40. doi: 10.1111/dom.12681. Epub 2016 Jun 6.
9
Fibrates down-regulate hepatic scavenger receptor class B type I protein expression in mice.贝特类药物可下调小鼠肝脏中I型清道夫受体B类蛋白的表达。
J Biol Chem. 2003 Mar 7;278(10):7884-90. doi: 10.1074/jbc.M211627200. Epub 2003 Jan 2.
10
Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.人精准切肝片中受 FXR 激动剂奥贝胆酸刺激的基因表达谱
J Hepatol. 2016 May;64(5):1158-1166. doi: 10.1016/j.jhep.2016.01.016. Epub 2016 Jan 23.

引用本文的文献

1
Humanized mouse liver reveals endothelial control of essential hepatic metabolic functions.人源化小鼠肝脏揭示了内皮细胞对肝脏基本代谢功能的控制作用。
Cell. 2023 Aug 31;186(18):3793-3809.e26. doi: 10.1016/j.cell.2023.07.017. Epub 2023 Aug 9.
2
Structure Optimization of 12β--γ-Glutamyl Oleanolic Acid Derivatives Resulting in Potent FXR Antagonist/Modulator for NASH Therapy.12β-γ-谷氨酰齐墩果酸衍生物的结构优化产生用于非酒精性脂肪性肝炎治疗的强效法尼醇X受体拮抗剂/调节剂
Pharmaceuticals (Basel). 2023 May 17;16(5):758. doi: 10.3390/ph16050758.
3
Aquaporin-8 ameliorates hepatic steatosis through farnesoid X receptor in obese mice.水通道蛋白8通过法尼酯X受体改善肥胖小鼠的肝脏脂肪变性。
iScience. 2023 Apr 1;26(4):106561. doi: 10.1016/j.isci.2023.106561. eCollection 2023 Apr 21.
4
Obeticholic Acid Induces Hepatoxicity Via FXR in the NAFLD Mice.奥贝胆酸通过法尼醇X受体在非酒精性脂肪性肝病小鼠中诱导肝毒性。
Front Pharmacol. 2022 May 9;13:880508. doi: 10.3389/fphar.2022.880508. eCollection 2022.
5
Modulation of Bile Acid Metabolism to Improve Plasma Lipid and Lipoprotein Profiles.调节胆汁酸代谢以改善血浆脂质和脂蛋白谱。
J Clin Med. 2021 Dec 21;11(1):4. doi: 10.3390/jcm11010004.
6
Euphornin L promotes lipid clearance by dual regulation of LDLR and PCSK9.喜果宁L通过对低密度脂蛋白受体(LDLR)和前蛋白转化酶枯草溶菌素9(PCSK9)的双重调节促进脂质清除。
Exp Ther Med. 2021 Dec;22(6):1381. doi: 10.3892/etm.2021.10817. Epub 2021 Sep 28.
7
FXR activation promotes intestinal cholesterol excretion and attenuates hyperlipidemia in SR-B1-deficient mice fed a high-fat and high-cholesterol diet.法尼酯X受体(FXR)激活可促进肠道胆固醇排泄,并减轻喂食高脂高胆固醇饮食的SR-B1基因缺陷小鼠的高脂血症。
Physiol Rep. 2020 Mar;8(5):e14387. doi: 10.14814/phy2.14387.
8
Obeticholic acid ameliorates dyslipidemia but not glucose tolerance in mouse model of gestational diabetes.奥贝胆酸可改善妊娠糖尿病小鼠模型的血脂异常,但不能改善葡萄糖耐量。
Am J Physiol Endocrinol Metab. 2019 Aug 1;317(2):E399-E410. doi: 10.1152/ajpendo.00407.2018. Epub 2019 Jun 25.
9
Activation of FXR by obeticholic acid induces hepatic gene expression of SR-BI through a novel mechanism of transcriptional synergy with the nuclear receptor LXR.奥贝胆酸通过激活法尼醇 X 受体(FXR),通过与核受体 LXR 的转录协同作用的新机制,诱导肝内清道夫受体 B1(SR-BI)的基因表达。
Int J Mol Med. 2019 May;43(5):1927-1938. doi: 10.3892/ijmm.2019.4136. Epub 2019 Mar 18.
10
Bile acids promote gastric intestinal metaplasia by upregulating CDX2 and MUC2 expression via the FXR/NF-κB signalling pathway.胆汁酸通过激活 FXR/NF-κB 信号通路上调 CDX2 和 MUC2 的表达促进胃肠化生。
Int J Oncol. 2019 Mar;54(3):879-892. doi: 10.3892/ijo.2019.4692. Epub 2019 Jan 22.

本文引用的文献

1
Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers.奥贝胆酸对健康志愿者脂蛋白代谢的影响。
Diabetes Obes Metab. 2016 Sep;18(9):936-40. doi: 10.1111/dom.12681. Epub 2016 Jun 6.
2
Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease.清道夫受体BI中的罕见变异会升高高密度脂蛋白胆固醇并增加冠心病风险。
Science. 2016 Mar 11;351(6278):1166-71. doi: 10.1126/science.aad3517.
3
Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia.6-(4-{[5-环丙基-3-(2,6-二氯苯基)异恶唑-4-基]甲氧基}哌啶-1-基)-1-甲基-1H-吲哚-3-羧酸的发现:一种用于治疗血脂异常的新型法尼醇X受体激动剂
J Med Chem. 2015 Dec 24;58(24):9768-72. doi: 10.1021/acs.jmedchem.5b01161. Epub 2015 Dec 2.
4
Future therapeutic targets for the treatment and prevention of cholesterol gallstones.治疗和预防胆固醇胆结石的未来治疗靶点。
Eur J Pharmacol. 2015 Oct 15;765:366-74. doi: 10.1016/j.ejphar.2015.08.045. Epub 2015 Sep 7.
5
Dysfunctional HDL and atherosclerotic cardiovascular disease.功能失调的高密度脂蛋白与动脉粥样硬化性心血管疾病。
Nat Rev Cardiol. 2016 Jan;13(1):48-60. doi: 10.1038/nrcardio.2015.124. Epub 2015 Sep 1.
6
MAFG is a transcriptional repressor of bile acid synthesis and metabolism.MAFG是胆汁酸合成与代谢的转录抑制因子。
Cell Metab. 2015 Feb 3;21(2):298-311. doi: 10.1016/j.cmet.2015.01.007.
7
Inhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1α protein expression through the ubiquitin-proteasome degradation pathway.黄连素对前蛋白转化酶枯草溶菌素9(PCSK9)转录的抑制作用涉及通过泛素-蛋白酶体降解途径下调肝脏中肝细胞核因子1α(HNF1α)蛋白的表达。
J Biol Chem. 2015 Feb 13;290(7):4047-58. doi: 10.1074/jbc.M114.597229. Epub 2014 Dec 24.
8
Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.奥贝胆酸治疗原发性胆汁性胆管炎患者对熊去氧胆酸应答不足的疗效。
Gastroenterology. 2015 Apr;148(4):751-61.e8. doi: 10.1053/j.gastro.2014.12.005. Epub 2014 Dec 11.
9
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.法尼醇X核受体配体奥贝胆酸治疗非肝硬化、非酒精性脂肪性肝炎(FLINT):一项多中心、随机、安慰剂对照试验
Lancet. 2015 Mar 14;385(9972):956-65. doi: 10.1016/S0140-6736(14)61933-4. Epub 2014 Nov 7.
10
The effects of diet on occlusive coronary artery atherosclerosis and myocardial infarction in scavenger receptor class B, type 1/low-density lipoprotein receptor double knockout mice.饮食对清道夫受体B类1型/低密度脂蛋白受体双敲除小鼠闭塞性冠状动脉粥样硬化和心肌梗死的影响。
Arterioscler Thromb Vasc Biol. 2014 Nov;34(11):2394-403. doi: 10.1161/ATVBAHA.114.304200. Epub 2014 Sep 11.

奥贝胆酸对高脂血症仓鼠脂质代谢的调节作用

Regulation of lipid metabolism by obeticholic acid in hyperlipidemic hamsters.

作者信息

Dong Bin, Young Mark, Liu Xueqing, Singh Amar Bahadur, Liu Jingwen

机构信息

Veterans Affairs Palo Alto Health Care System, Palo Alto, CA 94304.

Intercept Pharmaceuticals, Inc., San Diego, CA 92121.

出版信息

J Lipid Res. 2017 Feb;58(2):350-363. doi: 10.1194/jlr.M070888. Epub 2016 Dec 9.

DOI:10.1194/jlr.M070888
PMID:27940481
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5282951/
Abstract

The farnesoid X receptor (FXR) plays critical roles in plasma cholesterol metabolism, in particular HDL-cholesterol (HDL-C) homeostasis. Obeticholic acid (OCA) is a FXR agonist being developed for treating various chronic liver diseases. Previous studies reported inconsistent effects of OCA on regulating plasma cholesterol levels in different animal models and in different patient populations. The mechanisms underlying its divergent effects have not yet been thoroughly investigated. The scavenger receptor class B type I (SR-BI) is a FXR-modulated gene and the major receptor for HDL-C. We investigated the effects of OCA on hepatic SR-BI expression and correlated such effects with plasma HDL-C levels and hepatic cholesterol efflux in hyperlipidemic hamsters. We demonstrated that OCA induced a time-dependent reduction in serum HDL-C levels after 14 days of treatment, which was accompanied by a significant reduction of liver cholesterol content and increases in fecal cholesterol in OCA-treated hamsters. Importantly, hepatic SR-BI mRNA and protein levels in hamsters were increased to 1.9- and 1.8-fold of control by OCA treatment. Further investigations in normolipidemic hamsters did not reveal OCA-induced changes in serum HDL-C levels or hepatic SR-BI expression. We conclude that OCA reduces plasma HDL-C levels and promotes transhepatic cholesterol efflux in hyperlipidemic hamsters via a mechanism involving upregulation of hepatic SR-BI.

摘要

法尼醇X受体(FXR)在血浆胆固醇代谢中发挥关键作用,尤其是在高密度脂蛋白胆固醇(HDL-C)稳态方面。奥贝胆酸(OCA)是一种正在开发用于治疗各种慢性肝病的FXR激动剂。先前的研究报道了OCA在不同动物模型和不同患者群体中调节血浆胆固醇水平的效果不一致。其不同作用背后的机制尚未得到充分研究。B1型清道夫受体(SR-BI)是一种受FXR调节的基因,也是HDL-C的主要受体。我们研究了OCA对高脂血症仓鼠肝脏SR-BI表达的影响,并将这些影响与血浆HDL-C水平和肝脏胆固醇流出相关联。我们证明,在治疗14天后,OCA诱导血清HDL-C水平呈时间依赖性降低,同时OCA处理的仓鼠肝脏胆固醇含量显著降低,粪便胆固醇增加。重要的是,OCA处理使仓鼠肝脏SR-BI mRNA和蛋白质水平分别增加至对照的1.9倍和1.8倍。在正常血脂仓鼠中的进一步研究未发现OCA诱导血清HDL-C水平或肝脏SR-BI表达发生变化。我们得出结论,OCA通过上调肝脏SR-BI的机制降低高脂血症仓鼠的血浆HDL-C水平并促进肝脏胆固醇流出。